Dr. Daniel E. Weiner, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: Tufts University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
MA license 213380
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tufts Medical Center Boston, MA
- Emerson Hospital - W Concord, MA
- Cambridge Health Alliance Cambridge, MA
Medical groups
- Pratt Medical Group Inc (286 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 526
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Dialysis services, 4 or more physician visits per month (20 years or older) | 115 | 17 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 112 | 57 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 61 | 37 |
| Dialysis procedure including 1 evaluation | 40 | 12 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 31 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 18 |
| Hemodialysis procedure with physician evaluation | 20 | 18 |
| Hospital discharge day management, 30 minutes or less | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $254 in total to this clinician.
| Diality Inc. | $222 |
|---|---|
| Vantive US Healthcare LLC | $30.57 |
| Travere Therapeutics, Inc. | $1.66 |
| Food and Beverage | $253 |
|---|---|
| Education | $1.66 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Sep 12, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $55,399 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.